Daphne Karydas, Director at Mineralys Therapeutics, Inc. (MLYS), sold 3,000 shares at $28.58 ($86K) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($86k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MLYS | SELL | 2025-11-13 | $1.4M | — | Filing → |